Nurix Therapeutics, Inc. (NRIX) Cash Flow Statement
Nurix Therapeutics, Inc. (NRIX) generated $379.3M of operating cash flow over the twelve months to 2026-08-31, spent $9.5M on capital expenditure and had free cash flow of $369.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
NRIXNurix Therapeutics, Inc.Follow NRIX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- 10.0
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 26 Jan, in 93 days
| Line | FY2020 Nov 20 | FY2021 Nov 21 | FY2022 Nov 22 | FY2023 Nov 23 | FY2024 Nov 24 | FY2025 Nov 25 | TTM Aug 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.00 | -0.08 | -0.16 | -0.08 | -0.17 | -0.25 | 0.38 | |
| Capital expenditure | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.01 | |
| Free cash flow | -0.00 | -0.09 | -0.17 | -0.09 | -0.18 | -0.26 | 0.37 | |
| Stock-based compensation | 0.00 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | — |
USD billions · SEC XBRL
Nurix Therapeutics, Inc. — questions
- What is Nurix Therapeutics, Inc.'s operating cash flow?
- $379.3M over the twelve months to 2026-08-31.
- How much does Nurix Therapeutics, Inc. spend on capital expenditure?
- $9.5M over the twelve months to 2026-08-31.
- What is Nurix Therapeutics, Inc.'s free cash flow?
- $369.8M over the twelve months to 2026-08-31: operating cash flow minus capital expenditure.
Every figure on this page comes from Nurix Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.